JP Morgan Chase’s United Therapeutics UTHR Stock Holding History

JP Morgan Chase’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.81M	Sell	18,000 -127,300	-88%	-$71.7M	﹤0.01%	2819
2026 Q1	$85.5M	Buy	145,300 +144,900	+36,225%	+$72.2M	0.01%	1063
2025 Q4	$195K	Sell	400 -5,000	-93%	-$2.33M	﹤0.01%	5558
2025 Q3	$2.26M	Sell	5,400 -87,500	-94%	-$29.4M	﹤0.01%	3995
2025 Q2	$26.7M	Buy	92,900 +79,800	+609%	+$23.8M	﹤0.01%	1741
2025 Q1	$4.04M	Buy	+13,100	New	+$4.49M	﹤0.01%	3341
2024 Q3	–	Sell	-20,000	Closed	-$6.37M	–	7695
2024 Q2	$6.37M	Hold	20,000	–	–	﹤0.01%	2842
2024 Q1	$4.59M	Buy	+20,000	New	+$4.51M	﹤0.01%	3174
2023 Q2	–	Sell	-19,200	Closed	-$4.3M	–	7354
2023 Q1	$4.3M	Buy	+19,200	New	+$4.73M	﹤0.01%	2951
2018 Q2	–	Sell	-30,000	Closed	-$3.37M	–	5708
2018 Q1	$3.37M	Buy	+30,000	New	+$3.81M	﹤0.01%	2895
2015 Q2	–	Sell	-39,300	Closed	-$6.78M	–	4190
2015 Q1	$6.78M	Buy	+39,300	New	+$5.99M	﹤0.01%	2149

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase's UTHR Position: Q2 2026 in Review

JP Morgan Chase reduced its United Therapeutics (UTHR) stake by 5.6% in Q2 2026, selling an estimated $9.16M and leaving 275,358 shares worth $151M. The position accounts for 0.01% of the portfolio, ranked #868.

JP Morgan Chase first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $172M in Q1 2026. 881 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

JP Morgan Chase held 275,358 shares of United Therapeutics worth $151M as of Q2 2026.
JP Morgan Chase sold 16,263 United Therapeutics shares in Q2 2026, an estimated $9.16M.
United Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q2 2026, its #868 holding.
JP Morgan Chase first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's United Therapeutics position peaked at $172M in Q1 2026.
881 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.